ETEdward G. D. Tuddenham

Edward G. D. Tuddenham

*This is an algorithmically generated author record based on publicly available information.

Edward G. D. Tuddenham has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thrombin-mediated AutoRegulation of FVIII-mimetic antibodies enabling dynamic control of the hemostatic response

    by Vincent Muczynski, Angel Smith, Annalisa Baccaro, Dinusha Fernando, John-Paul Bukowski, Jenny Hazel McIntosh, Thibaud Sefiane, Olivier D. Christophe, Peter J Lenting, Kerry A. Chester, et al.

    Emicizumab has transformed hemophilia A (HA) management by enabling effective subcutaneous prophylaxis independent of inhibitor status. However, its constitutive activity and lack of sensitivity to anticoagulant feedback contribute to excessive thrombin generation under certain conditions, particularly when combined with bypassing agents, a liability increasingly recognized as a class effect of FVIII-mimetic antibodies. We engineered an "AutoRegulated" (AR) FVIII-mimetic antibody by integrating a short thrombin cleavable peptide sensitive to the proteolytic activity of thrombin in the hinge region of both emicizumab arms. Insertion of the peptide did not impair structural integrity and biological function with AR-emicizumab demonstrating EC50 values of FVIII-mimetic activity and correction of blood loss in HA mice comparable to the parental emicizumab. However, the presence of thrombin-mediated AR enabled thrombin-responsive proteolytic inactivation upon exposure to supra-physiological thrombin levels, whereas the parental emicizumab remained unaffected. The dynamic control provided by AR efficiently reduced the procoagulant effects induced by co-administration of activated Prothrombin Complex Concentrates (aPCC). In thrombin generation assays, AR-emicizumab significantly attenuated the excessive thrombin peak observed with emicizumab. Similarly, in vivo, the presence of thrombin-mediated AR prevented platelet consumptive coagulopathy and reduced the microvascular pulmonary thrombosis induced by the parental molecule without affecting the systemic levels of the therapeutic antibody. This on-demand self-limiting mechanism aligns therapeutic activity with local hemostatic needs, may offer a promising therapeutic approach for HA patients, while establishing a generalizable strategy to improve the safety profile of next-generation hemostatic biologics.

  • Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody

    by Vincent Muczynski, Olivier D. Christophe, Lewis Tanner, Charlotte Vayssiere, Alice Guérin, Caterina Casari, Jenny McIntosh, Doyoung Lee, Gavin Ling, Satyen Gohil, et al.

    The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.


  • Open Access

    Mathematical models of coagulation—are we there yet?

    by Matt J. Owen, Joy R. Wright, Edward G.D. Tuddenham, John R. King, Alison H. Goodall, Joanne L. Dunster


  • Open Access

    In search of the source of factor VIII

    by Edward Tuddenham


  • Open Access

    Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardian™ Trials.

    by Elena Santagostino, Steven R. Lentz, Mudi Misgav, Brigitte Brand, Pratima Chowdary, Aleksander Savic, Yurdanur Kilinc, Edward Gd Tuddenham, Anders Lindblom

    Abstract 2228


  • Molecular Biological Aspects of Inhibitor Development

    by E.G.D. Tuddenham

    Mutation genotype studies have led to a number of interesting observations about the role of the different types of mutations in inhibitor development. Searchable information on mutations, phenotype data, models, etc., are available on the internet at http://europium.mrc.rpms.ac.uk. A relatively high incidence of inhibitors occurs in patients with deletion mutations. Stop mutations are also associated with a high incidence of inhibitors, although there is anomalous distribution of the inhibitors associated with different stop codons. Inhibitors have been associated with a small number of missense mutations. Missense mutations are of great interest from the structure/function viewpoint; in many instances, a missense mutation which results in reduced function of a circulating protein can be mapped onto a model structure and inferences can be made about the effects on the functionality of the protein. A model of the A domains of FVIII is available, but as yet, no structure is available on which to model the C domain of FVIII. Stop codons appear to have a different incidence of inhibitor formation compared to other types of mutations. It is concluded that while genotype mutation studies have led to a number of interesting observations about the role of the different types of mutations in inhibitor development, though more questions have been raised than answers provided to date.


  • A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency

    by A. I. Wacey, S. Pemberton, D. N. Cooper, V. V. Kakkar, E. G. D. Tuddenham

    Summary. A molecular model of the serine protease domain of protein C was constructed by standard comparative methods. Individual missense mutations were inserted into the model and plausible explanations for their interference with protein C structure/function were derived through consideration of location, steric effects and protein stability. A hydrophilic cluster of many Arg and Lys residues, found adjacent to the active site cleft, is proposed to be involved in thrombomodulin and/or protein S interactions. Analysis of comparative binding studies also suggested the presence of an extended substrate binding pocket in the model.


  • Mutations in haemophilia A

    by R. Schwaab, J. Oldenburg, E. G. D. Tuddenham, H. H. Brackmann, K. Olek

    In the present study DNA from 281 unrelated haemophilia A patients including 15 inhibitor patients has been analysed by Southern blotting technique. Using various restriction enzymes, cloned factor VIII cDNA probes and genomic fragments we have identified 14 mutations. Six of the mutations are novel partial factor VIII gene deletions. One deletion affects exon 1, two deletions concern exon 6, another deletion, of which breakpoints are sequenced, takes part of exon 16 and two deletions affect exon 26. Besides the deletions, eight point mutations have been found at the TaqI restriction sites of exons 18, 24 and 26. Five C → T mutations resulted in nonsense mutations, one in exon 18, one in exon 26 and three in exon 24. Two G → A mutations caused a missense mutation in exon 24 leading to an arginine/glutamine exchange. Although two patients showed this mutation, their clinical phenotypes were different, possibly due to an additional unidentified sequence polymorphism. A G → T mutation in exon 26 substituted the arginine with leucine. All deletions and seven of the point mutations are associated with severe disease with a detectable inhibitor in the patient with the TaqI-point mutation in exon 18. One of the G → A mutations is associated with mild haemophilia but the patient also has developed an inhibitor. Amongst these mutations the origin of the mutation could be determined in four kindred, one of which showed maternal mosaicism.


  • CRM+ haemophilia A due to a missense mutation (372→Cys) at the internal heavy chain thrombin cleavage site

    by J. K. Pattinson, J. H. McVey, M. Boon, A. Ajani, E. G. D. Tuddenham

    We have used the polymerase chain reaction (PCR) and differential oligonucleotide melting to screen for mutations in selected CpG dinucleotides in the factor VIII genes of haemophilia A patients. By this means we have identified and confirmed by sequencing a novel point mutation in codon 372 (CGC) of the factor VIII gene of a moderately severe CRM+ haemophiliac. The first C of this codon has been substituted by T resulting in the non-conservative substitution of cysteine for arginine at an essential thrombin cleavage site in factor VIII. Analysis of three intragenic restriction fragment length polymorphisms was uninformative in the patient's family. However, DNA analysis for the specific mutation shows one sister and the patient's mother to be carriers, and the other sister to be normal. This DNA analysis confirmed the results of phenotype analysis by factor VIII coagulant to von Willebrand factor antigen ratios for the females at risk. The two carrier females had low factor VIII coagulant activity and excess VIII antigen as predicted but the non-carrier sister also had anomalously high VIII antigen in her plasma. When feasible, mutation specific DNA analysis is able to resolve the difficulties posed by variable phenotype data and unknown level of mutation in sporadic haemophilia A.